Branch of Imexpharm Corporation - Vinh Loc Hi-Tech Pharmacetical Antibiotic Plant

Imexpharm Pharmaceutical Joint Stock Company

Acid clavulanic (as Kali clavulanat - Syloid (1:1)); Amoxicilin (as Amoxicilin trihydrat powder)

250 mg / 31,25 mg

24 months

Powder for oral suspension

Box of 1 bag x 12 sachets x 1 g

893110271824

06/05/2024

Antibiotics

Amoxicillin/Clavulanic Acid 250 mg/31.25 mg should be used in accordance with antibiotic prescribing guidelines and local bacterial sensitivity data.
Amoxicillin/Clavulanic Acid 250 mg/31.25 mg is indicated for the short-term treatment of infections caused by amoxicillin/clavulanic acid-sensitive bacteria at the following sites:
- Upper respiratory tract infections (including ENT infections) such as recurrent tonsillitis, sinusitis, otitis media, typically caused by Streptococcus pneumoniae, Haemophilus influenzae¹, Moraxella catarrhalis¹, and Streptococcus pyogenes.
- Lower respiratory tract infections such as acute exacerbations of chronic bronchitis, lobar pneumonia, and bronchopneumonia, typically caused by Streptococcus pneumoniae, Haemophilus influenzae¹, and Moraxella catarrhalis¹.
- Genitourinary tract infections such as cystitis, urethritis, pyelonephritis, and female genital tract infections, typically caused by Enterobacteriaceae¹ (mainly Escherichia coli¹), Staphylococcus saprophyticus, Enterococcus spp., and gonorrhea caused by Neisseria gonorrhoeae¹.
- Skin and soft tissue infections, typically caused by Staphylococcus aureus¹, Streptococcus pyogenes, and Bacteroides spp¹.
- Bone and joint infections, such as osteomyelitis, typically caused by Staphylococcus aureus¹, usually requiring prolonged treatment.
- Other infections, such as infected miscarriage, postpartum infections, and intra-abdominal infections.
¹Some bacterial strains of these species produce beta-lactamase enzymes, rendering them resistant to amoxicillin when used alone (see section on Pharmacodynamic Properties).
Bacterial susceptibility to Amoxicillin/Clavulanic Acid 250 mg / 31.25 mg may vary according to geographical location and over time. Local epidemiological data on antimicrobial susceptibility should be consulted where available, and susceptibility testing should be performed when clinically indicated.
Mixed infections caused by amoxicillin-susceptible strains in conjunction with beta-lactamase-producing organisms susceptible to amoxicillin/clavulanic acid may be appropriately treated with this formulation.